Eleusian acquisition & three provisional patents propel GreenStar Biosciences into the exciting world of Transformational Medicine - (CSE:GSTR | OTC:GTSIF)

By James Moore


Mild traumatic brain injury (MTBI) – better known as concussion – is notoriously difficult to treat.

It affects as many as 2 million Americans each year.

While many patients tend to recover, subsequent mental health problems can have profound consequences on the rest of their lives.

For sufferers of post-traumatic stress disorder (“PTSD”) this is particularly acute.

The link between PTSD and concussion isn’t widely recognized.

Until relatively recently, the medical mainstream regularly misdiagnosed PTSD in those who had experienced concussion. Doctors would often incorrectly attribute a PTSD sufferer’s symptoms to post-concussion syndrome (PCS).

This misdiagnosis resulted in the administration of inappropriate and ineffective treatments, worsening the symptoms of what was actually PTSD to cause patients further distress and pain.

An unacceptably large number of former servicemen and women bore the brunt of this lack of understanding.

As many as 30% of combat veterans have reported suffering from PTSD.

Dealing with the mental health conditions of former service personnel is such a challenge that the U.S. Department of Veterans Affairs has allocated $10.2 billion in its 2021 budget to confront this crisis.

Concussion-inflicted PTSD is one of the main foes.

The trouble is that traditional therapies do not work nearly well enough.

Most people who receive a concussion – service personnel included – are simply advised to “wait it out”.

While this might succeed in alleviating the physical effects of the concussion (though even then that is a hit and miss gamble), it fails to address the traumatic experience that usually led to the concussion in the first place.

Questions have been asked about how best to resolve this issue in medical circles for a long time, but only very recent research has begun to provide some answers.

The key could lie in transformational medicines.

Transformational medicines represent a new branch of medical research, investigating the highly positive role psychedelic compounds could play in revolutionary new drugs to treat a broad range of mental health conditions.

Psychoactive substances, like MDMA, ketamine, and psilocybin are now being tested for their restorative powers.

The science has become so promising that regulatory authorities are quickly relaxing their stance towards these drugs and are even encouraging extensive research programs into their use.

Hundreds of millions of dollars have started to flow into the sector, in anticipation of creating a new frontier in drug discovery.

To emphasize how seriously U.S. authorities are taking the potential for transformational medicines consider that, in June, the U.S. Defense Advanced Research Projects Agency (DARPA) announced a $27 million research project into them to “create better psychiatric medicines.”

A number of companies have come to market over the last few months, hoping to capitalize on this immense opportunity.

However, one of the most recent entrants has an exceptionally compelling business case: GreenStar Biosciences (CSE:GSTR | OTC:GTSIF).

The phenomenal Eleusian Biosciences acquisition – a ready-made I.P. portfolio of transformational medicine projects

On 21 JulyGreenStar (CSE:GSTR | OTC:GTSIF) signed a definitive agreement to buy Eleusian Biosciences Corp., a privately-owned drug research and development company with immense potential in the transformational medicine space.

This deal was an amazing coup for GreenStar (CSE:GSTR | OTC:GTSIF) and its shareholders. It brought into the firm an almost unparalleled research capability and a pipeline of projects with blockbuster appeal.

Eleusian’s edge came a few years ago, when the firm’s founders learned about a remarkable new development at the University of Miami’s School of Medicine.

Here, researchers had revealed that an over-the-counter drug, n-acetylcysteine (“NAC”), could be a highly effective treatment for mTBI.

The team behind Eleusian immediately saw the great opportunity.

Driven by the belief that the mentally restorative properties of NAC could be combined with psychedelic compounds to make much more effective treatments, Eleusian forged a partnership with the University.

Together, they started to research and develop treatments for PTSD, pioneering this radically new approach.

This working relationship had already yielded two provisional patents.

Then, no sooner had the ink dried on the deal with GreenStar (CSE:GSTR | OTC:GTSIF), Eleusian announced it had filed its THIRD provisional patent.

This is the best possible news for GreenStar (CSE:GSTR | OTC:GTSIF), highlighting its immense speculative appeal moving forward.

Thanks to the Eleusian deal, GreenStar (CSE:GSTR | OTC:GTSIF) now has on its books these three extremely promising provisional patents:

The provisional patent for a combination therapy, using psilocybin and NAC for the treatment of mTBI with PTSD and PTSD alone

Another provisional patent for a combination therapy, using MDMA and NAC for the treatment of mTBI with PTSD and PTSD alone

A final provisional patent for a “nasal mist transducer” – a device that allows specific doses of different medicines to be sprayed into the nasal cavity and rapidly enter the bloodstream. GreenStar (CSE:GSTR | OTC:GTSIF) and Eleusian are now seeking strategic partners to build a prototype.

With such a comprehensive I.P. portfolio already in place following the Eleusian acquisition, GreenStar (CSE:GSTR | OTC:GTSIF) can now also pursue research into different applications of the NAC compound with other psychedelics.

The potential for pioneering drug discovery to treat a wide range of mental health conditions is immense:

From a standing start, GreenStar (CSE:GSTR | OTC:GTSIF) has broken into a sprint in the race to discover the first blockbuster transformational medicines.

Transformational medicines – a new dawn in drug discovery for GreenStar Biosciences (CSE:GSTR | OTC:GTSIF)

So, what is it that is causing so much interest in transformational medicines?

The simple answer is the science is so convincing.

Despite decades of political opposition to the use of psychedelic compounds in medicinal treatments, research carried on.

The incredible results, indicating the potential for long-term cures, could not be ignored.

Take psilocybin as an example.

One study by Johns Hopkins revealed a long-term success rate of 80% in a trial using repeated, small doses of psilocybin to treat anxiety in cancer patients.

In another study (results shown below), psilocybin was shown to be significantly more effective than any other treatment for depression over a sustained period of time.

Results from other research have been so impressive that the U.S. Food and Drug Administration (FDA) granted breakthrough therapy status for an MDMA-assisted psychotherapy for the treatment of PTSD in 2017. That is now underdoing Phase 3 clinical trials.

In 2018, the FDA awarded the same designation to the first psilocybin therapy aimed at healing treatment-resistant depression.

The FDA only awards this status to drug development programs that can demonstrate clear, preliminary clinical evidence that the new treatment can deliver a “substantial improvement” on at least one existing therapy.

More awards have since been granted, heralding a new dawn in drug discovery to cure mental health conditions.

With the research pedigree of Eleusian underpinning its new business model, GreenStar (CSE:GSTR | OTC:GTSIF) is now at the forefront of this exciting new field in blockbuster drug discovery.

This company’s focus on developing treatments for PTSD gives it a clear, competitive edge. Having already secured three provisional patents, GreenStar (CSE:GSTR | OTC:GTSIF) has a rich product pipeline and the opportunity to add to this through more research.

The second half of 2020 promises to be a thrilling ride for the company’s shareholders.


Paid Advertisement

This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Greenstar Biosciences Corp. to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of one hundred thousand USD to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.

Changes in Share Trading and Price

Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.

No Offer to Sell or Buy Securities

This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy.

No Financial Advice

The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.

Forward Looking Statements

This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.

Indemnification/Release of Liability

By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.

Terms of Use and Disclaimer

By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here https://www.valuethemarkets.com/terms-conditions/ and acknowledge that you have reviewed the Disclaimer found here: https://www.valuethemarkets.com/disclaimer/ . If you do not agree to the Terms of Use, please contact ValueTheMarkets.com to discontinue receiving future communications.

Intellectual Property

All trademarks used in this communication are the property of their respective trademark holders. Other than Valuethemarkets.com, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

Valuethemarkets.com.Ben Turney

Valuethemarkets.com and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above.

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

Ben Turney does not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. Ben Turney has been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of ValueTheMarkets.com, has been paid for the production this piece by the company or companies mentioned above.


In this article:

Author: James Moore

This article does not provide any financial advice and is not a recommendation to deal in any securities or product. Investments may fall in value and an investor may lose some or all of their investment. Past performance is not an indicator of future performance.

Sign up for Investing Intel Newsletter